Keith T Flaherty Selected Research

Melanoma (Melanoma, Malignant)

10/2022	Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
1/2022	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.
1/2022	Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128].
1/2022	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
1/2022	STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming.
1/2022	Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
1/2022	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study.
1/2022	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.
11/2021	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.
10/2021	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keith T Flaherty Research Topics

Disease

215	Melanoma (Melanoma, Malignant) 10/2022 - 03/2004
156	Neoplasms (Cancer) 10/2022 - 04/2003
24	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2009
23	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 11/2005
22	Disease Progression 01/2022 - 08/2009
8	Breast Neoplasms (Breast Cancer) 01/2022 - 03/2006
7	Brain Neoplasms (Brain Tumor) 01/2021 - 12/2009
7	Fatigue 01/2020 - 04/2004
7	Exanthema (Rash) 01/2020 - 06/2006
7	Hypertension (High Blood Pressure) 10/2018 - 11/2005
7	Neutropenia 03/2014 - 04/2003
5	Thrombocytopenia (Thrombopenia) 02/2005 - 04/2003
4	Inflammation (Inflammations) 01/2022 - 07/2014
4	Nevus (Nevi) 06/2021 - 06/2006
4	Fever (Fevers) 01/2021 - 11/2012
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 04/2010
4	Adenocarcinoma 01/2021 - 01/2017
4	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 04/2010
4	Nausea 01/2020 - 04/2004
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2014 - 06/2011
4	Keratoacanthoma 03/2014 - 06/2011
3	Lymphoma (Lymphomas) 10/2022 - 01/2020
3	Colonic Neoplasms (Colon Cancer) 01/2020 - 07/2015
3	Kidney Neoplasms (Kidney Cancer) 01/2020 - 01/2007
3	Uveal melanoma 12/2018 - 10/2013
3	Arthralgia (Joint Pain) 10/2018 - 06/2011
3	Glioblastoma (Glioblastoma Multiforme) 09/2016 - 04/2010
2	Pigmented Nevus (Melanocytic Nevus) 06/2021 - 09/2015
2	COVID-19 01/2021 - 10/2020
2	Skin Neoplasms (Skin Cancer) 01/2020 - 04/2010

Drug/Important Bio-Agent (IBA)

52	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 05/2006
34	VemurafenibIBA 01/2021 - 08/2010
33	Sorafenib (BAY 43-9006)FDA Link 01/2020 - 03/2006
29	Pharmaceutical PreparationsIBA 01/2020 - 07/2007
24	trametinibIBA 01/2022 - 07/2012
24	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2010
23	Immune Checkpoint InhibitorsIBA 01/2022 - 03/2013
22	dabrafenibIBA 01/2022 - 01/2011
18	Phosphotransferases (Kinase)IBA 01/2021 - 03/2008
14	Mitogen-Activated Protein KinasesIBA 01/2019 - 05/2006
13	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2014
10	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 12/2009
10	Proteins (Proteins, Gene)FDA Link 10/2020 - 06/2006
10	IpilimumabIBA 01/2018 - 01/2012
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2016 - 03/2006
9	Carboplatin (JM8)FDA LinkGeneric 01/2016 - 09/2003
9	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2016 - 08/2009
8	AntigensIBA 01/2022 - 07/2010
8	binimetinibIBA 01/2022 - 08/2016
8	Biological ProductsIBA 10/2021 - 04/2010
8	Paclitaxel (Taxol)FDA LinkGeneric 01/2016 - 09/2003
7	Sunitinib (Sutent)FDA Link 01/2020 - 07/2007
7	Dacarbazine (DIC)FDA LinkGeneric 01/2020 - 06/2011
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2012
6	encorafenibIBA 01/2022 - 01/2018
6	LigandsIBA 01/2018 - 06/2006
6	CytokinesIBA 01/2018 - 07/2009
5	cobimetinibIBA 01/2021 - 01/2018
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2019 - 01/2007
5	Transcription Factors (Transcription Factor)IBA 01/2019 - 01/2013
5	raf KinasesIBA 08/2017 - 03/2006
5	Imatinib Mesylate (Gleevec)FDA Link 08/2015 - 07/2008
4	InterferonsIBA 01/2022 - 03/2009
4	Interleukin-2 (IL2)IBA 06/2021 - 06/2014
4	Gemcitabine FDA Link 01/2020 - 09/2003
4	Monoclonal AntibodiesIBA 11/2019 - 03/2007
4	Proto-Oncogene Proteins B-rafIBA 01/2019 - 09/2010
4	Microphthalmia-Associated Transcription FactorIBA 01/2019 - 10/2014
4	PLX 4720IBA 08/2017 - 01/2012
4	AntibodiesIBA 09/2015 - 06/2006
4	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 09/2015 - 05/2006
4	Bevacizumab (Avastin)FDA Link 08/2015 - 05/2008
4	Angiogenesis InhibitorsIBA 01/2013 - 04/2008
3	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022 - 12/2012
3	B7-H1 AntigenIBA 01/2022 - 09/2017
3	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 06/2009
3	spartalizumabIBA 01/2022 - 10/2020
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2020 - 01/2016
3	TensinsIBA 10/2020 - 01/2016
3	Differentiation AntigensIBA 01/2020 - 01/2013
3	NivolumabIBA 01/2020 - 10/2013
3	Drug CombinationsIBA 01/2019 - 08/2017
3	pembrolizumabIBA 01/2018 - 10/2013
3	Small Interfering RNA (siRNA)IBA 09/2016 - 01/2013
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2016 - 01/2013
3	Tyrosine (L-Tyrosine)FDA Link 03/2012 - 10/2008
3	Cyclin-Dependent Kinase 4IBA 01/2012 - 07/2008
3	Cisplatin (Platino)FDA LinkGeneric 06/2009 - 04/2003
2	CohesinsIBA 01/2022 - 01/2016
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2014
2	Death Domain ReceptorsIBA 01/2022 - 01/2020
2	Axitinib (AG 013736)IBA 01/2022 - 11/2019
2	toripalimabIBA 01/2022 - 11/2019
2	EpitopesIBA 01/2021 - 01/2018
2	Hormones (Hormone)IBA 01/2021 - 01/2016

Therapy/Procedure

152	Therapeutics 10/2022 - 03/2004
34	Immunotherapy 01/2022 - 04/2006
16	Drug Therapy (Chemotherapy) 11/2019 - 04/2006
3	Precision Medicine 01/2018 - 02/2014
2	Neoadjuvant Therapy 01/2021 - 01/2019